Engineering virus-like particles as vaccine platforms.
Engineering virus-like particles as vaccine platforms.
复制标题
DOI：
10.1016/j.coviro.2016.03.001
复制
发表时间：
2016-06
影响因子：
5.9
通讯作者：
Chackerian B
中科院分区：
文献类型：
--
作者：
Frietze KM;Peabody DS;Chackerian B
病毒样颗粒（VLP）已被用作疫苗平台以增加异源抗原的免疫原性。多种多样的VLP类型可以用作疫苗平台，并且研究集中在工程化VLP以提高其作为疫苗的功效，增强其稳定性，并允许更通用的抗原展示。在这里，我们回顾了选定的VLP疫苗平台，强调通过结构知情的合理设计来改善这些平台的努力，并指出未来的研究领域，将有助于这些努力。
Virus-like particles (VLPs) have been utilized as vaccine platforms to increase the immunogenicity of heterologous antigens. A variety of diverse VLP types can serve as vaccine platforms, and research has focused on engineering VLPs to improve their efficacy as vaccines, enhance their stability, and allow for more versatile display of antigens. Here, we review selected VLP vaccine platforms, highlight efforts to improve these platforms through structure-informed rational design, and point to areas of future research that will assist in these efforts.